ADAPY

SEC source: 0001104659-23-078195 · tm2320409-8_4seq1.xml · derivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 736,548

Underlying: Ordinary Shares · 736,548 shares

Expires 2024-03-15

F1 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding restricted stock units with respect to TCRR common stock (each, a "TCRR RSU") were assumed by the Issuer and substituted for a restricted stock unit-style option to purchase Ordinary Shares (each, an "Adjusted Restricted Stock Unit Equivalent"), with an exercise price equal to GBP0.001, the nominal value of an Ordinary Share and on substantially similar terms and conditions as were applicable to such TCRR RSUs.

F2 · derivative.exercise_price: The number of Ordinary Shares subject to the Adjusted Restricted Stock Unit Equivalent is equal to (A) the ADS Exchange Ratio multiplied by six (such product, the "Ordinary Share Exchange Ratio") multiplied by (B) the total number of shares of TCRR common stock subject to such TCRR RSU. Each Adjusted Restricted Stock Unit Equivalent was granted to the Reporting Person on the date set out in Column 3.

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Currently exercisable.

SEC source: 0001104659-23-077673 · tm2320409-7_4seq1.xml · derivative · entry 1

Hegde Priti · CIK 0001880034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-077670 · tm2320409-6_4seq1.xml · derivative · entry 1

Furey John · CIK 0001691218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-077664 · tm2320409-2_4seq1.xml · derivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,462,927

Underlying: Ordinary Shares · 1,462,927 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount

SEC source: 0001104659-23-077662 · tm2320409-1_4seq1.xml · derivative · entry 1

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-077666 · tm2320409-3_4seq1.xml · derivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,077,756

Underlying: Ordinary Shares · 1,077,756 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-077669 · tm2320409-5_4seq1.xml · derivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 981,463

Underlying: Ordinary Shares · 981,463 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001209191-23-040641 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 933,317

Underlying: Ordinary Shares · 933,317 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-077668 · tm2320409-4_4seq1.xml · derivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 933,317

Underlying: Ordinary Shares · 933,317 shares

Expires 2033-07-03

F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-075407 · tm2317417-5_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,519

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 155,103 ADSs and RSU-style options and other options covering an aggregate of 27,496,302 ordinary shares of the Issuer.

SEC source: 0001104659-23-067118 · tm2317417-4_4.xml · nonDerivative · entry 3

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,931

F1 · security: Each American Depositary Share of the Issuer (each, an "ADS") represents six ordinary shares of the Issuer (each, an "Ordinary Share"), nominal value GBP 0.001 per Ordinary Share, of the Issuer.

F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub will be merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the "ADS Exchange Ratio"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share.

F7 · kind: Received 209,931 ADSs, representing 1,259,586 Ordinary Shares of the Issuer in exchange for 138,871 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F3 · price: Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F7 · price: Received 209,931 ADSs, representing 1,259,586 Ordinary Shares of the Issuer in exchange for 138,871 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

SEC source: 0001104659-23-067118 · tm2317417-4_4.xml · nonDerivative · entry 2

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,647

F1 · security: Each American Depositary Share of the Issuer (each, an "ADS") represents six ordinary shares of the Issuer (each, an "Ordinary Share"), nominal value GBP 0.001 per Ordinary Share, of the Issuer.

F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub will be merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the "ADS Exchange Ratio"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share.

F5 · kind: Received 200,647 ADSs, representing 1,203,882 Ordinary Shares in exchange for 132,730 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F3 · price: Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F5 · price: Received 200,647 ADSs, representing 1,203,882 Ordinary Shares in exchange for 132,730 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F6 · ownership.nature: ADSs held by the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust.

SEC source: 0001104659-23-067118 · tm2317417-4_4.xml · nonDerivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,646

F1 · security: Each American Depositary Share of the Issuer (each, an "ADS") represents six ordinary shares of the Issuer (each, an "Ordinary Share"), nominal value GBP 0.001 per Ordinary Share, of the Issuer.

F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub will be merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the "ADS Exchange Ratio"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share.

F3 · kind: Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub will be merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the "ADS Exchange Ratio"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share.

F3 · price: Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.

F4 · ownership.nature: ADSs held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust.

SEC source: 0001104659-23-008858 · tm231655-21_4seq1.xml · nonDerivative · entry 1

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,535

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.85 to $1.895, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 34,824 ADSs and RSU-style options and other options covering an aggregate of 5,845,530 ordinary shares of the Issuer.

SEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 3

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,480

Underlying: Ordinary Shares · 135,480 shares

Expires 2033-01-17

F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 2

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires 2033-01-17

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

SEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 1

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004381 · tm231655-19_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,264

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 107,907 ADSs and RSU-style options and other options covering an aggregate of 11,162,136 ordinary shares of the Issuer.

SEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 3

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,800

Underlying: Ordinary Shares · 202,800 shares

Expires 2025-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004379 · tm231655-17_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,351

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 141,752 ADSs and RSU-style options and other options covering an aggregate of 27,531,414 ordinary shares of the Issuer.

SEC source: 0001104659-23-004369 · tm231655-9_4seq1.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,798,272

Underlying: Ordinary Shares · 1,798,272 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 449,568 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 449,568 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004369 · tm231655-9_4seq1.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,690,224

Underlying: Ordinary Shares · 4,690,224 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 1,172,556 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 97,818 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 3

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,728

Underlying: Ordinary Shares · 193,728 shares

Expires 2033-01-17

F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 2

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires 2033-01-17

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

SEC source: 0001104659-23-004372 · tm231655-12_4seq1.xml · derivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004382 · tm231655-20_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,264

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 76,373 ADSs and RSU-style options and other options covering an aggregate of 7,911,108 ordinary shares of the Issuer.

SEC source: 0001104659-23-004380 · tm231655-18_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,491

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 42,797 ADSs and RSU-style options and other options covering an aggregate of 6,545,144 ordinary shares of the Issuer.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 3

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,920

Underlying: Ordinary Shares · 190,920 shares

Expires 2025-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004376 · tm231655-15_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004371 · tm231655-11_4seq1.xml · derivative · entry 3

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,344

Underlying: Ordinary Shares · 193,344 shares

Expires 2025-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004371 · tm231655-11_4seq1.xml · derivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004371 · tm231655-11_4seq1.xml · derivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 3

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,064

Underlying: Ordinary Shares · 197,064 shares

Expires 2033-01-17

F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires 2033-01-17

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 17, 2025 and January 17, 2026, and 78,564 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S. $1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 3

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,560

Underlying: Ordinary Shares · 181,560 shares

Expires 2025-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 2

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 1

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2033-01-17

F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

SEC source: 0001104659-23-003539 · tm231655-8_4seq1.xml · nonDerivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,121

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer.

SEC source: 0001104659-23-003534 · tm231655-5_4seq1.xml · nonDerivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,882

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 99,572 ADSs and RSU-style options and other options covering an aggregate of 21,183,366 ordinary shares of the Issuer.

SEC source: 0001104659-23-003538 · tm231655-7_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,121

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 61,982 ADSs and RSU-style options and other options covering an aggregate of 6,069,084 ordinary shares of the Issuer.

SEC source: 0001104659-23-003535 · tm231655-6_4seq1.xml · nonDerivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,191

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 24,336 ADSs and RSU-style options and other options covering an aggregate of 4,664,372 ordinary shares of the Issuer.

SEC source: 0001104659-23-003539 · tm231655-8_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,270

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer.

SEC source: 0001104659-23-003534 · tm231655-5_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,298

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 99,572 ADSs and RSU-style options and other options covering an aggregate of 21,183,366 ordinary shares of the Issuer.

SEC source: 0001104659-23-003538 · tm231655-7_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,270

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 61,982 ADSs and RSU-style options and other options covering an aggregate of 6,069,084 ordinary shares of the Issuer.

SEC source: 0001104659-23-003535 · tm231655-6_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,270

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 24,336 ADSs and RSU-style options and other options covering an aggregate of 4,664,372 ordinary shares of the Issuer.

SEC source: 0001104659-23-001092 · tm231655-4_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,781

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 87,735 ADSs and RSU-style options and other options covering an aggregate of 9,447,474 ordinary shares of the Issuer.